文献速递其他结缔组织病

根据抗黑素瘤分化相关基因5抗体状态评估皮肌炎或多发性肌炎合并间质性肺病患者自发性纵隔气肿的预后:一项回顾性队列研究

Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study.
PubMed 文献 · RMD Open · 2023-01-01

该回顾性队列研究纳入2016至2020年日本五家医院住院的119例皮肌炎/多发性肌炎合并间质性肺病患者,评估自发性纵隔气肿(SPNM)发生与死亡率的关系。SPNM组死亡率为34.8%,显著高于非SPNM组的7.3%(p=0.001);在抗MDA5抗体阳性患者中,SPNM组死亡率53.3%,显著高于无SPNM组的4.0%(p=0.001)。结论认为SPNM在抗MDA5抗体阳性患者中更常见,且与更高死亡风险相关。

要点

  • SPNM组死亡率34.8%,显著高于非SPNM组的7.3%(p=0.001)。
  • 抗MDA5抗体阳性患者中,SPNM组死亡率53.3%,显著高于无SPNM组的4.0%(p=0.001)。
  • SPNM组全部死亡均发生于抗MDA5抗体阳性患者(8/15),抗体阴性者无死亡(0/8)。

核心结论

  • SPNM在抗MDA5抗体阳性皮肌炎/多发性肌炎合并间质性肺病患者中比抗体阴性患者更常见。
  • SPNM发生与更高死亡风险相关,尤其在抗MDA5抗体阳性患者中。

研究设计与样本

  • 回顾性观察性研究,纳入2016至2020年在日本五家医院住院的皮肌炎/多发性肌炎合并间质性肺病患者。
  • 共分析119例患者,收集基线特征(包括肌炎特异性自身抗体)、治疗、SPNM及自治疗开始或强化后1年内死亡的数据。
  • 比较SPNM组与非SPNM组的基线特征和结局。

主要发现

  • 119例患者中23例发生SPNM,15例死亡;SPNM患者中15例为抗MDA5抗体阳性。
  • SPNM组死亡率为34.8%,非SPNM组为7.3%,差异有统计学意义(p=0.001)。
  • SPNM组全部死亡均发生在抗MDA5抗体阳性患者中(8/15),抗MDA5抗体阴性的SPNM患者无死亡(0/8)。
  • 在抗MDA5抗体阳性患者中,SPNM组死亡率为53.3%,无SPNM组为4.0%,差异有统计学意义(p=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Spontaneous pneumomediastinum (SPNM) historically has been considered a poor prognostic factor in dermatomyositis/polymyositis patients complicated with interstitial lung disease (ILD). However, there is a lack of actual data regarding the association between SPNM occurrence and mortality in dermatomyositis/polymyositis patients. This study aimed to assess the association between SPNM occurrence and mortality in myositis patients with ILD according to antimelanoma differentiation-associated gene 5 (MDA5) antibody status. METHODS: Dermatomyositis/polymyositis patients with ILD who were hospitalised at five Japanese hospitals from 2016 to 2020 were included in this retrospective observational study. We collected data about baseline characteristics including myositis-specific autoantibodies, treatments, SPNM and death within 1 year from therapy initiation or strengthening. Baseline characteristics and outcomes were compared between patients with and without SPNM (the SPNM group and the non-SPNM group, respectively). RESULTS: A total of 119 patients were analysed. SPNM occurred in 23 patients, and 15 patients died. Fifteen patients with SPNM were anti-MDA5 antibody positive. The mortality rate was significantly higher in the SPNM group (34.8%) than in the non-SPNM group (7.3%) (p=0.001). All deaths in the SPNM group occurred in anti-MDA5 antibody-positive patients (8/15), whereas none of the anti-MDA5 antibody-negative patients in the SPNM group died (0/8). In anti-MDA5 antibody-positive patients, the mortality rate was significantly higher in patients with SPNM occurrence (53.3%) than in those without SPNM occurrence (4.0%) (p=0.001). CONCLUSION: SPNM occurred more frequently in anti-MDA5 antibody-positive than in anti-MDA5 antibody-negative myositis patients. SPNM occurrence was associated with higher mortality risk, especially in anti-MDA5 antibody-positive patients.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Abe K, Furuta S, Kobayashi Y, et al. Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study. RMD Open. 2023. PMID: 36759007. doi:10.1136/rmdopen-2022-002770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。